PMID- 30840220
OWN - NLM
STAT- MEDLINE
DCOM- 20200212
LR  - 20200212
IS  - 2240-2993 (Electronic)
IS  - 0300-9009 (Linking)
VI  - 119
IP  - 3
DP  - 2019 Sep
TI  - Lacosamide in patients with intellectual disability and refractory epilepsy.
PG  - 423-430
LID - 10.1007/s13760-019-01098-3 [doi]
AB  - The objective of this study was to evaluate the tolerability and efficacy of 
      lacosamide (LCM) in residential patients at our epilepsy centre. We assessed 
      retrospectively 80 patients (mean age 36.2 years, range 18-63 years; 29 female) 
      with intellectual disability (ID) and drug-resistant epilepsy using an 
      industry-independent, non-interventional study design based on standardised 
      seizure records. Evaluation, including calculation of retention rate, was carried 
      out for the intervals 3-6, 9-12 and 21-24 months after LCM initiation. The 
      Clinical Global Impression scale (CGI) was used to allow assessment of 
      qualitative changes in seizure severity and clinical status. CGI improved for 61% 
      of the patients. The responder rate was 48%; ten patients (13%) became seizure 
      free. The response was not related to the degree of ID. The retention rates after 
      12 and 24 months were 71% and 65%, and were significantly lower in patients 
      taking other sodium-channel blockers (SCBs; 76% vs. 55%). The occurrence of 
      adverse events (AEs) was related to the administration of concomitant SCBs (48% 
      with SCBs vs. 26% without). Sedation (15%), ataxia (13%), vertigo (11%), and 
      nausea (9%) were the commonest AEs. While 60% of our patients had concomitant 
      psychiatric diagnosis, we found no relevant effect of this on challenging 
      behaviour. Adjunctive LCM may provide an antiepileptic treatment option for 
      patients with ID with or without additional psychiatric diagnosis. The occurrence 
      of AEs and the LCM retention rate were affected by concomitant SCB use but not by 
      psychiatric comorbidity.
FAU - Kleist, Anika
AU  - Kleist A
AUID- ORCID: 0000-0003-0062-8976
AD  - Department of Neurology and Epilepsy Center, Sana-Krankenhaus Rummelsberg 
      (Teaching Hospital of the Friedrich-Alexander-Universitat Erlangen-Nurnberg), 
      Rummelsberg 71, 90592, Schwarzenbruck, Germany.
FAU - Kerling, Frank
AU  - Kerling F
AD  - Department of Neurology and Epilepsy Center, Sana-Krankenhaus Rummelsberg 
      (Teaching Hospital of the Friedrich-Alexander-Universitat Erlangen-Nurnberg), 
      Rummelsberg 71, 90592, Schwarzenbruck, Germany.
FAU - Hamer, Hajo
AU  - Hamer H
AD  - Department of Neurology, Friedrich-Alexander-Universitat Erlangen-Nurnberg, 
      Schwabachanlage 6, 91054, Erlangen, Germany.
FAU - Winterholler, Martin
AU  - Winterholler M
AD  - Department of Neurology and Epilepsy Center, Sana-Krankenhaus Rummelsberg 
      (Teaching Hospital of the Friedrich-Alexander-Universitat Erlangen-Nurnberg), 
      Rummelsberg 71, 90592, Schwarzenbruck, Germany.
LA  - eng
PT  - Journal Article
DEP - 20190306
PL  - Italy
TA  - Acta Neurol Belg
JT  - Acta neurologica Belgica
JID - 0247035
RN  - 0 (Anticonvulsants)
RN  - 0 (Voltage-Gated Sodium Channel Blockers)
RN  - 563KS2PQY5 (Lacosamide)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anticonvulsants/adverse effects/*pharmacology
MH  - Comorbidity
MH  - Drug Resistant Epilepsy/*drug therapy/epidemiology
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - *Intellectual Disability/epidemiology
MH  - Lacosamide/adverse effects/*pharmacology
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Voltage-Gated Sodium Channel Blockers/adverse effects/*pharmacology
MH  - Young Adult
OTO - NOTNLM
OT  - Antiepileptic drug
OT  - Intellectual disability
OT  - Lacosamide
OT  - Refractory epilepsy
EDAT- 2019/03/07 06:00
MHDA- 2020/02/13 06:00
CRDT- 2019/03/07 06:00
PHST- 2018/09/20 00:00 [received]
PHST- 2019/02/13 00:00 [accepted]
PHST- 2019/03/07 06:00 [pubmed]
PHST- 2020/02/13 06:00 [medline]
PHST- 2019/03/07 06:00 [entrez]
AID - 10.1007/s13760-019-01098-3 [pii]
AID - 10.1007/s13760-019-01098-3 [doi]
PST - ppublish
SO  - Acta Neurol Belg. 2019 Sep;119(3):423-430. doi: 10.1007/s13760-019-01098-3. Epub 
      2019 Mar 6.